MDNA(Delisted)
MedicennaยทNASDAQ
--
--(--)
MDNA Profile
Medicenna Therapeutics Corp.
A clinical stage immunotherapy company that develops and commercializes Empowered Cytokines and Superkines for the treatment of cancer
2 Bloor St. W., 7th Floor, Toronto, Ontario M4W 3E2
--
Medicenna Therapeutics Corp. was incorporated as an A2 acquisition company on February 2, 2015 under the Alberta Business Companies Act. The Company is a clinical-stage immuno-oncology company that develops novel, highly selective interleukins (" IL-2 "), interleukin-4 (" IL-4 ") and interleukin-13 modulating cytokines known as "Superkines". These superfactors can either be developed alone as short- or long-term therapeutic drugs, or they can be fused with cell killer proteins to produce authorizing cytokines (" ECs ") that precisely deliver potent toxins to cancer cells without harming adjacent healthy cells.
